describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR
Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021 After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac. Investigators collected and recorded the following data: * Age * Gender * Systemic hypertension (present or not) * Smoking (Yes / No) * Best corrected visual acuity (BCVA) (baseline, final) * Central macular thickness (CMT) (baseline, final) * Serous detachment Height (SDH) (baseline, final) * Duration of Follow-up ( in months)
Study Type
OBSERVATIONAL
Enrollment
16
Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
Kasr alainy faculty of medicine
Cairo, Egypt
Change in central macular thickness (CMT ) in microns
reduction in CMT after therapy
Time frame: (baseline, 6 months)
Change in serous detachment height (SDH) in microns
reduction in SDH after therapy
Time frame: (baseline, 6 months)
Change in BCVA
number of lines of improvement in BCVA after therapy
Time frame: (baseline, 6 months)
Duration of Follow-up ( in months)
Duration of Follow-up ( in months)
Time frame: (baseline, 6 months)
Complications (Eplerenone, Aflibercept, and nepafenac)
present or absent
Time frame: (baseline, 6 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.